tirzepatide once weekly in Children and Adolescents with Type 2 Diabetes (SURPASS-Peds). The New England Journal of Medicine. 2024;391:XXX–XXX. doi:10.1056/NEJMoa2400938 Tirzepatide (Mounjaro) for the Treatment

In the COMBINE 2 trial in individuals with T2D inadequately controlled with GLP-1RA, with or without additional oral glucose-lowering medications, IcoSema as compared to semaglutide 1.0 mg provided superiority in HbA 1c reduction from baseline to week 52 and greater improvement in fasting plasma glucose with comparable rate of combined clinically significant or severe hypoglycemia, while the weight change was in favor of semaglutide 1.0 mg [14]

Improved Health Metrics : They help lower blood sugar, reduce cholesterol, and improve cardiovascular health

Standard Effective Dose After assessing tolerance, most men move to 1.52.0 mg

Notably, 38% of patients experienced no adverse events during the 24-week treatment, a proportion higher than typically seen with other anti-obesity agents [22]

H.SantosA